![]() ![]() HIPAA, Human Subject Protection (HSP), InvestigationĮnhancing the Diversity of Clinical Trial Populations - Eligibility Criteria, Enrollment Practices, and Trial Designsĭesign, Diversity, Ethics Committee (EC), Ethnicity, Gender, Good Clinical Practice (GCP), Human Subject Protection (HSP)Ĭivil Money Penalties Relating to the Data BankĬivil Money Penalties, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigator, 1572 Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1) Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies Guidance for Industry Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Productsĭigital Health Technologies for Remote Data Acquisition in Clinical Investigations Tissue Agnostic Drug Development in OncologyĬharacterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical TrialsĮthical Considerations for Clinical Investigations of Medical Products Involving Children Real World Data/Real World Evidence (RWD/RWE)Ĭlinical Investigator Administrative Actions - Disqualificationĭisqualification, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigator, InspectionĪcute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment Decentralized Clinical Trials for Drugs, Biological Products, and DevicesĮlectronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and AnswersĬonsiderations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
0 Comments
Leave a Reply. |